BrainsWay Deep TMS™



Boldly Advancing Neuroscience to Improve Health and Transform Lives

chs®

BrainsWay®

www.brainsway.com

A Significant Unmet Need Exists in the Treatment of Mental Health and Addiction Conditions

Current treatment options, including pharmacotherapy, psychotherapy, and electroconvulsive therapy, are not working for a substantial population of patients.



MEDICATION

Diminishing clinical benefit and increasing incidence of intolerable side effects are seen with successive pharmacological treatments.

VS.



PSYCHOTHERAPY

Lengthy treatment is required, and may not be sufficient for patients with more severe symptoms.

VS.



ELECTROCONVULSIVE THERAPY (ECT)

Offers limited appeal to patients due to public stigma, anesthesia requirements, and potential short-term memory loss.

VS.

Who is BrainsWay?

BrainsWay is a NASDAQ and TASE-listed medical device company, founded in 2003 to commercialize the revolutionary Deep TMS treatment platform, based on patents co-developed with the National Institutes of Health (NIH).

What is Deep TMS?

A neurostimulation technology that uses a magnetic coil to activate neural networks in target areas of the brain implicated in mental health disorders.

BrainsWay Offers a New Tool for Treatment-Resistant Patients Using Cutting-Edge Neuroscience

Deep Transcranial Magnetic Stimulation (Deep TMS™) is a well-established technology backed by significant published clinical evidence and successful use throughout influential academic institutions and private clinics.

BrainsWay Deep TMS

Clinically proven to help many patients who do not respond to one or more pharmaceuticals, with no systemic side effects, as often seen with drugs.

Shown in clinical research to help many patients who do not respond to psychotherapy and incorporates personalized behavioral elements to reinforce treatment.

Can be done in an outpatient setting without anesthesia and is free of memory loss or other cognitive side effects.






Superior Science

Advanced H-Coil Design

BrainsWay's unique coil design enables deeper and broader stimulation than traditional, figure-8 TMS coils, resulting in greater activation of neurons, less likelihood of targeting errors, and powerful efficacy.





H1 Coil for Major Depressive Disorder (MDD)


H7 Coil for Obsessive-Compulsive Disorder (OCD)

H4 Coil for Smoking Addiction

Traditional TMS Coil for Major Depressive Disorder (MDD)

Electric Field Distribution Map

The deeper and broader field distribution of Deep TMS™ is apparent in these 6 MRI coronal slices





Better User Experience

BrainsWay's touchscreen interface guides the operator through determination of coil positioning and intensity, allowing quicker setup than traditional TMS systems.

BrainsWay's H-Coils are integrated into a cushioned, cooled helmet, allowing the patient to retain mobility during the treatment without compromising treatment accuracy.



A Platform for Mental Health and Addiction Treatment

Deep TMS, uniquely offered by BrainsWay, uses patented H-Coils embedded in a patient and operator-friendly helmet to noninvasively activate deep and broad brain structures that can address a range of mental health conditions.

H1 COIL

FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) / ANXIOUS DEPRESSION





Stimulates the prefrontal cortex, particularly the left dorsolateral prefrontal cortex



- In addition to numerous published, double-blind, randomized controlled trials validating the efficacy of Deep TMS for depression, **clinical data of over 1,300 patients in real practice settings has shown compelling results**.
- Among patients who completed at least 30 sessions, **greater than 4 in 5 achieved response and approximately 2 in 3 achieved remission**.

Standard 20-minute sessions or Intermittent Theta Burst (iTBS) 3-min sessions with 20 sessions across 4 weeks, followed by 10-16 sessions across additional 5-8 weeks

H7 COIL

FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)





Stimulates the anterior cingulate cortex and prefrontal cortex



- Complementing a large scale, double-blind, multicenter randomized controlled trial which demonstrated strong response rates, **greater than 1 in 2 patients who completed 29 sessions in real clinical practice achieved sustained response**.

Standard 18-minute sessions with 29 sessions across 6 weeks

H4 COIL

FOR THE TREATMENT OF SMOKING ADDICTION





Stimulates the bilateral insula and prefrontal cortex



- **Nearly 1 in 3 patients that completed 18 sessions achieved 4 or more weeks of abstinence from smoking** in a large scale, double-blind, multicenter randomized controlled trial. 2 of 3 patients who quit smoking by the end of treatment, remained abstinent for at least an additional 3 months.
- Many additional patients experienced **significant reduction in average number of cigarettes smoked per week**.

Standard 18-minute sessions with 18 sessions across 6 weeks

Superior Evidence

Superior Research

BrainsWay is the only TMS provider with Health Canada clearance backed by clinically proven efficacy for Depression, OCD, and Smoking Addiction.



BrainsWay's commitment to scientific rigor and excellence is unrivaled by any other TMS company. Deep TMS has been validated in 60+ sham-controlled trials (RCTs) involving over 3,000 patients. Research on Deep TMS has led to 300+ publications.



Proven Clinical Superiority

An independent, head-to-head study of TMS technologies determined that Deep TMS plus standard medication was significantly more effective at reducing depression levels among Major Depressive Disorder (MDD) patients compared with Traditional TMS plus medication or medication alone.

*The Magstim® Rapid² device was used in this study. (Magstim Company, Spring Gardens, UK)

Superior Support

Unrivaled Partnership Programs

- Clinic Workflow
- Marketing Support
- Patient Identification
- Reimbursement Support
- Clinical Training
- Service & Maintenance



BrainsWay's Practice Development Consultants work closely with you to build the skills and capabilities that lead to sustainable success.

Attractive Business Model

With strong Medicare and private payer reimbursement rates for Deep TMS treatment of depression, **your practice only requires a modest number of patients to generate substantial positive cash flow.**


More than 1 in 3 depression patients are likely candidates for Deep TMS and BrainsWay can help you identify them!

BrainsWay offers a strong return-on-investment with flexible payment options that allow you to build your Deep TMS practice at your desired pace.

BrainsWay®

A Win for Your Practice and Patients

Your treatment-resistant patients have a lot at stake. Give them hope for a better life with BrainsWay Deep TMS.



Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
Am J Psychiatry 2006; 163:1905-17

Tendler A, et al. Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis. Psychiatry Research. Vol 324, June 2023, 115179

Roth Y, et al. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites.
J Psychiatr Res. 2020 Nov 4;S0022-3956(20)31065-7

Zangen A et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial.
World Psychiatry. 2021 Oct;20(3):397-404

Filipčić et al. (2019) Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder;
A randomized clinical trial. Journal of Psychiatric Research 114: 113-119

Zibman et al. An In-Depth Look at BrainsWay Technology (Deep TMS). BrainsWay White Paper (2018)



Learn More About Whether Deep TMS Technology is Right for Your Practice

You can:

- ☑ **SPEAK** with a **CHS** representative
- ☑ **SCAN** the QR code for more information
- ☑ **VISIT** the Knowledge Center at www.brainsway.com
- ☑ **CALL** us at **905-825-9300**
- ☑ **EMAIL** us at **customercare@chsltd.com**

SCAN ME

Indications — BrainsWay Deep TMS is indicated by the FDA:

- For the treatment of depressive episodes and for decreasing Anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. FDA 510(k) No. K122288 (Model 102), FDA 510(k) No. K173540 (Model 104), FDA 510(k) No. K210201, No. K203735 (Models 102 & 104)
- As an intended adjunct treatment for adult patients suffering from Obsessive-Compulsive Disorder (OCD). FDA De Novo No. DEN170078 (Model 102) and FDA 510(k) No. K183303 (Model 104)
- As an aid in short-term smoking cessation for adults. FDA 510(k) No. K200957 (Model 102) and FDA 510(k) No. K203616 (Model 104)

Safety Information — Patients should consult with their doctor before undergoing BrainsWay Deep TMS. The most common side effects include headaches and application site pain or discomfort. There is also a very rare risk of seizure associated with the treatment. Patients with metal in or around the head as in metal plates, implants, and stents should not undergo Deep TMS treatment.

chs®

BrainsWay®

www.brainsway.com

BrainsWay and Deep TMS are trademarks of
BrainsWay Ltd. ©2023 BrainsWay. All Rights Reserved

BW-TMS-44 rev. 05/2023
MKT-0001-00 v1